Cambridge Investment Research Advisors
ATRA icon

Cambridge Investment Research Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,864
Closed -$414K – 3937
2025
Q4 		$414K Buy
22,864
+5,755
+34% +$85.9K ﹤0.01% 2902
2025
Q3 		$245K Buy
+17,109
New +$197K ﹤0.01% 3307

Other funds holding ATRA

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cambridge Investment Research Advisors's ATRA Position: Q1 2026 in Review

Cambridge Investment Research Advisors sold out of Atara Biotherapeutics (ATRA) in Q1 2026, closing a stake of 22,864 shares — an estimated $414K sold.

Cambridge Investment Research Advisors first reported a position in ATRA in Q3 2025 and held it in 2 quarters. The position peaked at $414K in Q4 2025. 33 funds tracked by Wall St. Rank hold ATRA as of Q1 2026.

  • Cambridge Investment Research Advisors reported no remaining Atara Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 22,864 Atara Biotherapeutics shares in Q1 2026, an estimated $414K.
  • Cambridge Investment Research Advisors first reported a position in Atara Biotherapeutics in Q3 2025 and held it in 2 quarters.
  • Cambridge Investment Research Advisors's Atara Biotherapeutics position peaked at $414K in Q4 2025.
  • 33 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.